ibidi Extends its LifeAct(TM) Product Line for Visualization of the Actin Cytoskeleton

(PresseBox) ( Munich, Germany, )
ibidi GmbH, a supplier of solutions for analyzing living cells, extends its LifeAct(TM) product line for undisturbed visualization of Actin cytoskeleton organization and dynamics.

ibidi's new Actin marker, LifeAct(TM) , binds to the structure protein without constraining its activity. For long-term actin visualization, ibidi is now offering a stable LifeAct expressing fibrosarcoma cell line (HT-1080 LifeAct-TagGFP2). This cell line shows identical characteristics and behavior to the parental HT-1080 cell line and guarantees a minimum of 25 passages with undisturbed LifeAct expression. ibidi paid special attention to the functional characterization of the cell line, so as to prove that it is optimized for cell-based assays such as migration, chemotaxis, and wound healing. Further LifeAct expressing cell lines, including basic and functional characterization studies, are also currently under development.

Since 2010, LifeAct has been available from ibidi as a plasmid coding for the peptide and a red or green fluorescent protein. The plasmid is used for the easy transfection of various cell types and for the generation of stably expressing cell lines. One example is to use it in combination with ibidi's new transfection reagent Torpedo DNA, which has been optimized for microscopic assays using ibidi's µ-Slides and µ-Dishes. ibidi also offers an adenoviral vector coding for LifeAct. This viral approach makes it possible to access difficult-to-transfect cells, such as primary cells.

Finally, ibidi presents an extended, new range of cell line services (in cooperation with SIRION BIOTECH), which completes its current group of cell biology products. The available services are: the provision of custom-specific stable cell pools in less than 7 weeks, FACS, a clonal cell line service, and a functional cell characterization that provides customers with maximum flexibility in experimental design, strong gene expression / knockdown, and validated, functionally-tested stable cell pools.

"ibidi consistently pursues the goal of offering complete solutions for live cell imaging", states Dr. Roman Zantl, co-founder and head of R&D at ibidi GmbH. "With the further extension of the LifeAct product line, including the new cell line services, ibidi establishes its lead position of being a provider of solutions for functional, cell-based assays in migration, chemotaxis, or angiogenesis for cancer research, cell biology and immunology."
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.